KOL Perspectives: Views on initial Phase III data for etrolizumab in IBD
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› Questions topics:
›Views on etrolizumab Phase III efficacy data in Crohn’s disease
›Expected use of etrolizumab in Crohn’s disease
›Views on etrolizumab Phase III efficacy data in UC
›Expected use of etrolizumab in UC›Improving Trial Enrollment
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during December 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Broadly positive KOLs suggest etrolizumab Phase III data is an improvement on vedolizumab (VDZ) Phase III results Crohn’s disease
Majority of KOLs view etrolizumab's efficacy to be comparable to VDZ, but consider its efficacy as inferior to anti-TNFs
Majority of KOLs expect to use etrolizumab as a second/third-line therapy in the Crohn’s disease treatment algorithm
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on "etrolizumab Phase III data in UC & Crohn's disease"
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Genentech
Takeda
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Gastrointestinal reports

